Profarma (B3: PFRM3) financial statements
The consolidated income statement, balance sheet and cash flow statement of Profarma for its last 10 fiscal years, as filed with the regulator, in millions of Brazilian reais. At the end of fiscal 2025 it had BRL 6,234m in total assets and BRL 1,346m in equity.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | BRL 11,451m | BRL 10,154m | BRL 8,662m | BRL 7,816m | BRL 6,413m | BRL 5,481m | BRL 4,801m | BRL 4,271m | BRL 4,101m | BRL 4,085m |
| Cost of sales | BRL 9,700m | BRL 8,631m | BRL 7,370m | BRL 6,671m | BRL 5,506m | BRL 4,718m | BRL 4,063m | BRL 3,590m | BRL 3,400m | BRL 3,459m |
| Gross profit | BRL 1,750m | BRL 1,523m | BRL 1,292m | BRL 1,146m | BRL 907.6m | BRL 763.6m | BRL 737.8m | BRL 680.9m | BRL 701.0m | BRL 625.3m |
| Operating profit | BRL 350.0m | BRL 299.7m | BRL 261.1m | BRL 242.9m | BRL 130.7m | BRL 120.6m | BRL 60.9m | BRL 54.9m | −BRL 11.3m | BRL 76.2m |
| Profit before tax | BRL 117.5m | BRL 127.9m | BRL 81.6m | BRL 79.0m | BRL 48.7m | BRL 33.1m | BRL 21.6m | −BRL 30.1m | −BRL 153.6m | −BRL 52.4m |
| Income tax | −BRL 8.6m | BRL 5.0m | BRL 3.7m | −BRL 6.1m | −BRL 30.4m | −BRL 28.6m | BRL 9.6m | −BRL 20.4m | −BRL 40.9m | −BRL 3.5m |
| Net profit | BRL 118.9m | BRL 114.6m | BRL 70.4m | BRL 80.9m | BRL 78.2m | BRL 52.3m | BRL 12.0m | −BRL 9.7m | −BRL 112.7m | −BRL 49.0m |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | BRL 6,234m | BRL 5,616m | BRL 4,938m | BRL 4,365m | BRL 4,033m | BRL 3,761m | BRL 3,183m | BRL 2,890m | BRL 2,619m | BRL 2,712m |
| Current assets | BRL 4,494m | BRL 4,020m | BRL 3,539m | BRL 2,980m | BRL 2,582m | BRL 2,484m | BRL 2,096m | BRL 1,953m | BRL 1,645m | BRL 1,693m |
| Cash | BRL 235.1m | BRL 229.6m | BRL 193.7m | BRL 183.3m | BRL 188.5m | BRL 371.8m | BRL 225.8m | BRL 229.2m | BRL 193.2m | BRL 205.5m |
| Total liabilities | BRL 4,599m | BRL 4,030m | BRL 3,399m | BRL 2,854m | BRL 2,557m | BRL 2,326m | BRL 2,179m | BRL 1,869m | BRL 1,874m | BRL 1,953m |
| Current liabilities | BRL 3,485m | BRL 2,989m | BRL 2,447m | BRL 1,956m | BRL 1,717m | BRL 1,544m | BRL 1,576m | BRL 1,412m | BRL 1,577m | BRL 1,157m |
| Equity | BRL 1,346m | BRL 1,303m | BRL 1,248m | BRL 1,191m | BRL 1,086m | BRL 1,046m | BRL 1,005m | BRL 1,021m | BRL 745.9m | BRL 759.0m |
| Equity including minorities | BRL 1,636m | BRL 1,586m | BRL 1,539m | BRL 1,511m | BRL 1,476m | BRL 1,435m | BRL 1,005m | BRL 1,021m | BRL 745.9m | BRL 759.0m |
| Minority interests | BRL 289.8m | BRL 282.7m | BRL 290.7m | BRL 319.6m | BRL 389.8m | BRL 388.9m | BRL 0.0m | BRL 0.0m | BRL 0.0m | BRL 0.0m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | BRL 459.7m | BRL 497.1m | BRL 260.9m | BRL 126.3m | BRL 107.6m | BRL 39.3m | BRL 126.9m | −BRL 55.8m | −BRL 51.8m | −BRL 107.3m |
| Investing cash flow | −BRL 176.1m | −BRL 136.8m | −BRL 96.6m | −BRL 21.7m | −BRL 86.4m | −BRL 47.7m | −BRL 31.7m | −BRL 31.7m | −BRL 102.1m | −BRL 117.1m |
| Financing cash flow | −BRL 278.0m | −BRL 324.4m | −BRL 153.8m | −BRL 109.8m | −BRL 204.4m | BRL 154.4m | −BRL 98.6m | BRL 123.5m | BRL 141.6m | BRL 176.9m |
| Dividends paid | −BRL 76.7m | −BRL 54.6m | −BRL 31.2m | — | −BRL 29.1m | — | — | — | — | — |
Where each figure comes from
From the annual financial statements (DFP) that Profarma files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the Profarma page.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.